Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer"

被引:0
作者
Kikuchi, Eiji [1 ]
Hayakawa, Nozomi [1 ]
机构
[1] St Marianna Univ, Sch Med, Dept Urol, Kawasaki, Kanagawa, Japan
关键词
RANDOMIZED PHASE-III; METHOTREXATE; VINBLASTINE; DOXORUBICIN;
D O I
10.1111/iju.15541
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1106 / 1106
页数:1
相关论文
共 4 条
[1]   Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer [J].
Hattori, Yuto ;
Fujiwara, Tasuku ;
Hagimoto, Hiroki ;
Kokubun, Hidetoshi ;
Murata, Shiori ;
Makita, Noriyuki ;
Abe, Yohei ;
Kubota, Masashi ;
Tohi, Yoichiro ;
Tsutsumi, Naofumi ;
Shibasaki, Noboru ;
Inoue, Koji ;
Kawakita, Mutsushi ;
Yamasaki, Toshinari .
INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (10) :1102-1106
[2]   Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209 [J].
Kitamura, H. ;
Tsukamoto, T. ;
Shibata, T. ;
Masumori, N. ;
Fujimoto, H. ;
Hirao, Y. ;
Fujimoto, K. ;
Kitamura, Y. ;
Tomita, Y. ;
Tobisu, K. ;
Niwakawa, M. ;
Naito, S. ;
Eto, M. ;
Kakehi, Y. .
ANNALS OF ONCOLOGY, 2014, 25 (06) :1192-1198
[3]  
nccn, NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines) Anal Carcinoma Version 3.2023
[4]   Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses [J].
Pfister, Christian ;
Gravis, Gwenaelle ;
Flechon, Aude ;
Soulie, Michel ;
Guy, Laurent ;
Laguerre, Brigitte ;
Mottet, Nicolas ;
Joly, Florence ;
Allory, Yves ;
Harter, Valentin ;
Culine, Stephane .
EUROPEAN UROLOGY, 2021, 79 (02) :214-221